par prism | Sep 1, 2022 | Publications
Gurvan Hermange, Alicia Rakotonirainy, Mahmoud Bentriou, Amandine Tisserand, Mira El-Khoury, François Girodon, Christophe Marzac, William Vainchenker, Isabelle Plo, Paul-Henry Cournède: Inferring the initiation and development of myeloproliferative neoplasms. Dans:...
par prism | Juil 1, 2022 | News
Prof. Fabrice André, MD, PhD, Head of the Research Division at Gustave Roussy Cancer Campus, France, will be the European Society for Medical Oncology (ESMO) President 2025-2026. ESMO Directors of Education, Membership and Public Policy have also been appointed for...
par prism | Oct 10, 2021 | Study
The PRISM-I trial promoted by Gustave Roussy and Prism began on October 5, 2021. The objectives of this study are to: i. define the effectiveness of anti-PDL1 antibodies at 6 weeks, ii. decipher the immune response at the single cell and spatial level. 200 patients...
par prism | Oct 15, 2020 | News, Partenariats
The “Prism-Breast” project aims to understand the determinants of tumor response to anti-PD1 and beyond in patients who develop early stage triple negative breast cancer. Triple negative breast cancers represent 15% of breast cancers and most often have a...
![CentralSupélec Podcast on Prism [Fr]](https://prism.center/wp-content/uploads/2020/10/podcast-800x675.jpg)
par prism | Oct 7, 2020 | Médias, News
The CentralSupélec podcast La recherche au service de la santé dedicated an issue to Prism with Fabrice André and Paul-Henry Cournède: Listen the podcast...